09.30 | 6.30 – Regulatory Guidance for Liquid Biopsy Applications in Clinical Programs

Time: 9:30 am
day: Day Three


  • Data assembly considerations for regulatory review
  • Regulatory considerations for varying LBx applications and profiling technologies
  • Endpoint considerations in clinical trial design
  • Establishing ctDNA changes as a surrogate marker in the metastatic and adjuvant settings